RxDoctor Payments Data

Erik Kerekes, MD

Gastroenterology · Long Beach, CANPI 1871679340

Payments from drug & device makers

$59,116in general payments, 2019–2025

Across 582 payments — averaging $101.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$32K
  • Boehringer Ingelheim$12K
  • Boehringer Ingelheim RCV GmbH & Co KG$6K
  • AbbVie$2K
  • Medtronic$1K
  • Johnson & Johnson$877
  • plus $6K from 38 others

What the payments were for

  • Travel & lodging$98910%
  • Food & beverage$8,61589%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,116 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$179,470
Medicare patients
488
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$312,101
CreonLipase/Protease/Amylase20$44,521
LinzessLinaclotide22$15,171
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates189$11,772
MotegrityPrucalopride Succinate11$6,655
Erythromycin Ethylsuccinate11$6,003
Pantoprazole Sodium350$3,729
Mesalamine11$3,311
Dexlansoprazole DrDexlansoprazole15$2,999
Lubiprostone11$2,506
SutabSod Sulf/Pot Chloride/Mag Sulf15$2,380
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,048
CholestyramineCholestyramine (With Sugar)27$1,694
Famotidine133$1,241
Omeprazole63$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$877$312,10113 claims
AbbVieCreon, Linzess$1,932$59,69142 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$259$6,65511 claims
Braintree Laboratories, Inc.Sutab$38$2,38015 claims
Ferring Pharmaceuticals Inc.Clenpiq$214$2,04812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →